Charles Russell Speechlys advises Apposite Capital on acquisition of i2a Diagnostics

Charles Russell Speechlys has advised healthcare investor Apposite Capital on the management buy in of microbiology company i2a Diagnostics.

Created in 1988, i2a is a leading provider of laboratory instruments, software and reagents for the clinical microbiology market in France. The company specialises in offering automated solutions across the value chain of the bacteriology clinical testing market, including Antibiotic Sensitivity Testing which identifies bacterial resistance to antibiotics.

Anne-Laure Meynier, Investment Director at Apposite Capital, who will join the Board of i2a said: “With 700,000 deaths worldwide annually, antimicrobial resistance is a global health priority and Apposite believes that more solutions will be needed to fight it. i2a sees significant opportunities in supporting labs and clinicians with best-in-class solutions to adjust therapy and transform data into actionable insights and we are delighted to be working with the i2a Founding team on this exciting new investment.”

Thibaut Caharel, Corporate Partner at Charles Russell Speechlys commented: “We were delighted to assist Anne-Laure and the Apposite team on this transaction. We wish both Apposite and i2a every success as they continue to execute their international growth strategy in this important domain of research and software-enabled Antimicrobial Susceptibility testing solutions.”

The Charles Russell Speechlys team, led by Corporate Partner Thibaut Caharel, included Guillaume Ferrand (Corporate), Kim Campion and Laure de Ganay (Employment), and Raphaël Bagdassarian and Elea Reyes (Tax).